Order of the General Court of 10 April 2024 – Biogen Netherlands v Commission

(Case T-278/22) ¹

(Action for annulment – Public health – Medicinal products for human use – Decision to grant marketing authorisation for Dimethyl fumarate Neuraxpharm – dimethyl fumarate – Repeal of the contested decision – Action which has become devoid of purpose – No need to adjudicate)

Language of the case: English

Parties

Applicant: Biogen Netherlands BV (Amsterdam, Netherlands) (represented by: C. Schoonderbeek and B. Jong, lawyers)

Defendant: European Commission (represented by: K. Mifsud Bonnici, A. Sipos and E. Mathieu, acting as Agents)

Re:

By its application based on Article 263 TFEU, the applicant seeks annulment of Commission Implementing Decision C(2022) 3254 final of 13 May 2022 granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for Dimethyl fumarate Neuraxpharm – dimethyl fumarate as a medicinal product for human use.

Operative part of the order

There is no longer any need to adjudicate on the action.

Biogen Netherlands BV and the European Commission shall bear their own costs, including those relating to the proceedings for interim measures.

____________

¹     OJ C 284, 25.7.2022.